Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Economy & Forex  >  All News

News : Economy & Forex

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors 
All NewsEconomyCurrencies / ForexCryptocurrenciesEconomic EventsPress releases

Exclusive- Carlyle explores sale or IPO of Ortho-Clinical Diagnostics: sources

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 08:16am CEST
A general view of the lobby outside of the Carlyle Group offices in Washington

(Reuters) - Private equity firm Carlyle Group LP (>> The Carlyle Group LP) is exploring a sale or initial public offering of Ortho-Clinical Diagnostics Inc, a U.S. diagnostics company that could be valued at more than $7 billion, including debt, people familiar with the matter said.

(Reuters) - Private equity firm Carlyle Group LP (>> The Carlyle Group LP) is exploring a sale or initial public offering of Ortho-Clinical Diagnostics Inc, a U.S. diagnostics company that could be valued at more than $7 billion, including debt, people familiar with the matter said.

A divestment of Ortho-Clinical Diagnostics, which Carlyle acquired from Johnson & Johnson (>> Johnson & Johnson) in 2014 for $4 billion, would show how buyout firms can turn unloved businesses of major corporations into lucrative investments within a few years.

Carlyle has hired investment banks to run a sale process for Ortho-Clinical, the sources said this week. Carlyle may also pursue an IPO of the company if the offers it receives do not meet valuation expectations, the sources added.

The sources asked not to be identified because the deliberations are confidential.

Carlyle declined to comment. Ortho-Clinical Diagnostics did not respond to a request for comment.

Headquartered in Raritan, New Jersey, Ortho-Clinical produces in-vitro diagnostics equipment and associated assays and reagents. It generates about $1.7 billion in annual revenue and employs about 4,300 people worldwide, according to its website.

Ortho-Clinical has incurred significant expenses in the last three years to find its footing as a standalone company. These implementation and restructuring costs are expected to taper off by the end of the year, as it severs most of its ties with Johnson & Johnson, according to credit ratings agency Moody's Investors Service Inc.

The company sells its products in more than 125 countries, but has potential to grow in emerging markets, according to Moody's.

Any deal for Ortho-Clinical would likely come in the first half of 2018, making it one of the first major Carlyle portfolio companies to be divested under the leadership of Glenn Youngkin and Kewsong Lee, who are set to become co-chief executive officers of Carlyle in January, taking over the reins from founders David Rubenstein, William Conway and Daniel D'Aniello.

Carlyle has a long track record of investing in healthcare companies and has been seeking to cash out on some of them this year. In April, Carlyle agreed to sell down part of its 60 percent stake in U.S. clinical trials firm Pharmaceutical Product Development LLC at a $9.05 billion corporate valuation.

(Reporting by Greg Roumeliotis and Carl O'Donnell in New York; Editing by Leslie Adler)

By Greg Roumeliotis and Carl O'Donnell

Stocks treated in this article : Johnson & Johnson, The Carlyle Group LP
Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON -1.69% 140.47 Delayed Quote.2.26%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Economy & Forex"
01:06pIn latest change, Uber launches 24/7 phone support in Britain
RE
01:05pCorporate Canada takes side bet with FX hedges as NAFTA risk intensifies
RE
01:05pIDS Completes TRID 2.0 Updates to Mortgage Document Preparation Platform
SE
01:05pSimplifile Adds 29 Southeastern U.S. Counties to E-recording Network
SE
01:01pIndonesia's Pertamina backs $100 billion spend to boost oil output
RE
12:59pJRC JOINT RESEARCH CENTRE : How the European pulp and paper industry can achieve a 62% reduction in annual greenhouse gas emissions by 2050
PU
12:59pAFRICAN UNION : Sub-Committee of Directors General of Customs Express Commitment to Combat Corruption in Customs to effectively implement the AfCFTA
PU
12:54pMalta watchdog says EU has dropped its anti-money-laundering probe
RE
12:45pTHE DAILY MACRO BRIEF : Inflation in Europe, Brexit saga and the UN
12:44pEUROBAROMETER : 4 out of 5 EU citizens support private sector in development cooperation
PU
Latest news "Economy & Forex"
Advertisement